Tachykinin receptor 1 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tachykinin receptor 1" in English language version.

refsWebsite

Global rank English rank

30nih.gov

4^th place

21doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

2ensembl.org

1,626^th place

1,007^th place

doi.org

Takeda Y, Chou KB, Takeda J, Sachais BS, Krause JE (September 1991). "Molecular cloning, structural characterization and functional expression of the human substance P receptor". Biochemical and Biophysical Research Communications. 179 (3): 1232–1240. doi:10.1016/0006-291X(91)91704-G. PMID 1718267.
Ho WZ, Douglas SD (December 2004). "Substance P and neurokinin-1 receptor modulation of HIV". Journal of Neuroimmunology. 157 (1–2): 48–55. doi:10.1016/j.jneuroim.2004.08.022. PMID 15579279. S2CID 14975995.
Page NM (August 2005). "New challenges in the study of the mammalian tachykinins". Peptides. 26 (8): 1356–1368. doi:10.1016/j.peptides.2005.03.030. PMID 16042976. S2CID 23094292.
Datar P, Srivastava S, Coutinho E, Govil G (2004). "Substance P: structure, function, and therapeutics". Current Topics in Medicinal Chemistry. 4 (1): 75–103. doi:10.2174/1568026043451636. PMID 14754378.
Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, et al. (August 2004). "Tachykinins and tachykinin receptors: structure and activity relationships". Current Medicinal Chemistry. 11 (15): 2045–2081. doi:10.2174/0929867043364748. PMID 15279567.
Satake H, Kawada T (August 2006). "Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors". Current Drug Targets. 7 (8): 963–974. doi:10.2174/138945006778019273. PMID 16918325.
Seto S, Tanioka A, Ikeda M, Izawa S (March 2005). "Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists". Bioorganic & Medicinal Chemistry Letters. 15 (5): 1479–1484. doi:10.1016/j.bmcl.2004.12.091. PMID 15713411.
Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–992. doi:10.2174/138945006778019381. PMID 16918326.
Humphrey JM (2003). "Medicinal chemistry of selective neurokinin-1 antagonists". Current Topics in Medicinal Chemistry. 3 (12): 1423–1435. doi:10.2174/1568026033451925. PMID 12871173.
Saria A (June 1999). "The tachykinin NK1 receptor in the brain: pharmacology and putative functions". European Journal of Pharmacology. 375 (1–3): 51–60. doi:10.1016/S0014-2999(99)00259-9. PMID 10443564.
Quartara L, Maggi CA (December 1997). "The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation". Neuropeptides. 31 (6): 537–563. doi:10.1016/S0143-4179(97)90001-9. PMID 9574822. S2CID 13735836.
Humphrey JM (2003). "Medicinal chemistry of selective neurokinin-1 antagonists". Current Topics in Medicinal Chemistry. 3 (12): 1423–1435. doi:10.2174/1568026033451925. PMID 12871173.
Duffy RA (May 2004). "Potential therapeutic targets for neurokinin-1 receptor antagonists". Expert Opinion on Emerging Drugs. 9 (1): 9–21. doi:10.1517/eoed.9.1.9.32956. PMID 15155133.
Schank JR (October 2014). "The neurokinin-1 receptor in addictive processes". The Journal of Pharmacology and Experimental Therapeutics. 351 (1): 2–8. doi:10.1124/jpet.113.210799. PMID 25038175. S2CID 16533561.
Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, Fan J, et al. (January 2008). "Family-based association study of lithium-related and other candidate genes in bipolar disorder". Archives of General Psychiatry. 65 (1): 53–61. doi:10.1001/archgenpsychiatry.2007.15. PMID 18180429.
Munoz M, Covenas R, Esteban F, Redondo M (June 2015). "The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs". Journal of Biosciences. 40 (2): 441–463. doi:10.1007/s12038-015-9530-8. PMID 25963269. S2CID 3048287.
Jordan K (February 2006). "Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy". Onkologie. 29 (1–2): 39–43. doi:10.1159/000089800. PMID 16514255. S2CID 34016787.
Esteban F, Ramos-García P, Muñoz M, González-Moles MÁ (December 2021). "Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature". International Journal of Environmental Research and Public Health. 19 (1): 375. doi:10.3390/ijerph19010375. PMC 8751191. PMID 35010633.
Coveñas R, Muñoz M (July 2022). "Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer". Cancers. 14 (14): 3539. doi:10.3390/cancers14143539. PMC 9317685. PMID 35884599.
Muñoz M, Coveñas R (2016). "Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach". Saudi Journal of Gastroenterology. 22 (4): 260–268. doi:10.4103/1319-3767.187601. PMC 4991196. PMID 27488320.
Muñoz M, González-Ortega A, Salinas-Martín MV, Carranza A, Garcia-Recio S, Almendro V, et al. (October 2014). "The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer". International Journal of Oncology. 45 (4): 1658–1672. doi:10.3892/ijo.2014.2565. PMID 25175857.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000115353 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000030043 – Ensembl, May 2017

nih.gov

pubmed.ncbi.nlm.nih.gov

Takeda Y, Chou KB, Takeda J, Sachais BS, Krause JE (September 1991). "Molecular cloning, structural characterization and functional expression of the human substance P receptor". Biochemical and Biophysical Research Communications. 179 (3): 1232–1240. doi:10.1016/0006-291X(91)91704-G. PMID 1718267.
Ho WZ, Douglas SD (December 2004). "Substance P and neurokinin-1 receptor modulation of HIV". Journal of Neuroimmunology. 157 (1–2): 48–55. doi:10.1016/j.jneuroim.2004.08.022. PMID 15579279. S2CID 14975995.
Page NM (August 2005). "New challenges in the study of the mammalian tachykinins". Peptides. 26 (8): 1356–1368. doi:10.1016/j.peptides.2005.03.030. PMID 16042976. S2CID 23094292.
Datar P, Srivastava S, Coutinho E, Govil G (2004). "Substance P: structure, function, and therapeutics". Current Topics in Medicinal Chemistry. 4 (1): 75–103. doi:10.2174/1568026043451636. PMID 14754378.
Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, et al. (August 2004). "Tachykinins and tachykinin receptors: structure and activity relationships". Current Medicinal Chemistry. 11 (15): 2045–2081. doi:10.2174/0929867043364748. PMID 15279567.
Satake H, Kawada T (August 2006). "Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors". Current Drug Targets. 7 (8): 963–974. doi:10.2174/138945006778019273. PMID 16918325.
Graefe SB, Mohiuddin SS (April 2022). Biochemistry, Substance P. Treasure Island, FL: StatPearls Publishing. PMID 32119470. Retrieved 28 January 2023.
Seto S, Tanioka A, Ikeda M, Izawa S (March 2005). "Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists". Bioorganic & Medicinal Chemistry Letters. 15 (5): 1479–1484. doi:10.1016/j.bmcl.2004.12.091. PMID 15713411.
Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–992. doi:10.2174/138945006778019381. PMID 16918326.
Humphrey JM (2003). "Medicinal chemistry of selective neurokinin-1 antagonists". Current Topics in Medicinal Chemistry. 3 (12): 1423–1435. doi:10.2174/1568026033451925. PMID 12871173.
Saria A (June 1999). "The tachykinin NK1 receptor in the brain: pharmacology and putative functions". European Journal of Pharmacology. 375 (1–3): 51–60. doi:10.1016/S0014-2999(99)00259-9. PMID 10443564.
Quartara L, Maggi CA (December 1997). "The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation". Neuropeptides. 31 (6): 537–563. doi:10.1016/S0143-4179(97)90001-9. PMID 9574822. S2CID 13735836.
Humphrey JM (2003). "Medicinal chemistry of selective neurokinin-1 antagonists". Current Topics in Medicinal Chemistry. 3 (12): 1423–1435. doi:10.2174/1568026033451925. PMID 12871173.
Duffy RA (May 2004). "Potential therapeutic targets for neurokinin-1 receptor antagonists". Expert Opinion on Emerging Drugs. 9 (1): 9–21. doi:10.1517/eoed.9.1.9.32956. PMID 15155133.
Schank JR (October 2014). "The neurokinin-1 receptor in addictive processes". The Journal of Pharmacology and Experimental Therapeutics. 351 (1): 2–8. doi:10.1124/jpet.113.210799. PMID 25038175. S2CID 16533561.
Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, Fan J, et al. (January 2008). "Family-based association study of lithium-related and other candidate genes in bipolar disorder". Archives of General Psychiatry. 65 (1): 53–61. doi:10.1001/archgenpsychiatry.2007.15. PMID 18180429.
Munoz M, Covenas R, Esteban F, Redondo M (June 2015). "The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs". Journal of Biosciences. 40 (2): 441–463. doi:10.1007/s12038-015-9530-8. PMID 25963269. S2CID 3048287.
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, et al. (2015). "Management of Insomnia Disorder". Comparative Effectiveness Reviews. 159. PMID 26844312.
Jordan K (February 2006). "Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy". Onkologie. 29 (1–2): 39–43. doi:10.1159/000089800. PMID 16514255. S2CID 34016787.
Esteban F, Ramos-García P, Muñoz M, González-Moles MÁ (December 2021). "Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature". International Journal of Environmental Research and Public Health. 19 (1): 375. doi:10.3390/ijerph19010375. PMC 8751191. PMID 35010633.
Coveñas R, Muñoz M (July 2022). "Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer". Cancers. 14 (14): 3539. doi:10.3390/cancers14143539. PMC 9317685. PMID 35884599.
Muñoz M, Coveñas R (2016). "Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach". Saudi Journal of Gastroenterology. 22 (4): 260–268. doi:10.4103/1319-3767.187601. PMC 4991196. PMID 27488320.
Muñoz M, González-Ortega A, Salinas-Martín MV, Carranza A, Garcia-Recio S, Almendro V, et al. (October 2014). "The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer". International Journal of Oncology. 45 (4): 1658–1672. doi:10.3892/ijo.2014.2565. PMID 25175857.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Graefe SB, Mohiuddin SS (April 2022). Biochemistry, Substance P. Treasure Island, FL: StatPearls Publishing. PMID 32119470. Retrieved 28 January 2023.
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, et al. (2015). "Management of Insomnia Disorder". Comparative Effectiveness Reviews. 159. PMID 26844312.
Esteban F, Ramos-García P, Muñoz M, González-Moles MÁ (December 2021). "Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature". International Journal of Environmental Research and Public Health. 19 (1): 375. doi:10.3390/ijerph19010375. PMC 8751191. PMID 35010633.
Coveñas R, Muñoz M (July 2022). "Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer". Cancers. 14 (14): 3539. doi:10.3390/cancers14143539. PMC 9317685. PMID 35884599.
Muñoz M, Coveñas R (2016). "Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach". Saudi Journal of Gastroenterology. 22 (4): 260–268. doi:10.4103/1319-3767.187601. PMC 4991196. PMID 27488320.

semanticscholar.org

api.semanticscholar.org

Ho WZ, Douglas SD (December 2004). "Substance P and neurokinin-1 receptor modulation of HIV". Journal of Neuroimmunology. 157 (1–2): 48–55. doi:10.1016/j.jneuroim.2004.08.022. PMID 15579279. S2CID 14975995.
Page NM (August 2005). "New challenges in the study of the mammalian tachykinins". Peptides. 26 (8): 1356–1368. doi:10.1016/j.peptides.2005.03.030. PMID 16042976. S2CID 23094292.
Quartara L, Maggi CA (December 1997). "The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation". Neuropeptides. 31 (6): 537–563. doi:10.1016/S0143-4179(97)90001-9. PMID 9574822. S2CID 13735836.
Schank JR (October 2014). "The neurokinin-1 receptor in addictive processes". The Journal of Pharmacology and Experimental Therapeutics. 351 (1): 2–8. doi:10.1124/jpet.113.210799. PMID 25038175. S2CID 16533561.
Munoz M, Covenas R, Esteban F, Redondo M (June 2015). "The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs". Journal of Biosciences. 40 (2): 441–463. doi:10.1007/s12038-015-9530-8. PMID 25963269. S2CID 3048287.
Jordan K (February 2006). "Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy". Onkologie. 29 (1–2): 39–43. doi:10.1159/000089800. PMID 16514255. S2CID 34016787.